Plain-English translation of NCT07257510 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether , , and work together to treat mantle cell lymphoma—a type of blood cancer—in people who haven't been treated before. The study will give patients the three medications together for six months (called the "induction" phase), and then patients whose cancer responds well will continue taking two of the medications for up to 18 more months (called the "maintenance" phase). The goal is to see how many people achieve a complete response and how long they stay cancer-free.
Mantle cell lymphoma is a serious blood cancer, and doctors want to find the most effective first treatment. This medication combination targets cancer cells in new ways, and doctors believe using all three together may work better than existing treatments.
You likely qualify if…
You likely don't qualify if…
If you join, you will take three medications for six months: one pill by mouth daily, another pill by mouth daily, and an infusion through an IV once a month. After six months, doctors will test your blood to see if the cancer is no longer detectable. If it is not detectable, you will continue taking two of the medications (one pill daily and one IV infusion every few months) for up to 18 more months. You will have regular clinic visits, blood tests, and imaging scans throughout the study to monitor how you are responding.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
China